Showing 3531-3540 of 19350 results for "".
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
https://reachmd.com/programs/project-oncology/axatilimab-for-cgvhd-assessing-organ-specific-responses-in-agave-201/36313/An analysis of the AGAVE-201 trial presented at the European Hematology Association 2025 Congress evaluated the organ-specific responses to axatilimab in patients with chronic graft-versus-host disease (cGVHD). Finding a range of effects, these results could offer new insights into dose optimizationQuick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
https://reachmd.com/programs/cme/quick-case-strategizing-treatment-selection-in-her2-pd-l1-gastric-cancer/37692/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingTackling Fluid Overload in Patients with Heart Failure: Novel Approaches to Remote Monitoring
https://reachmd.com/programs/cme/tackling-fluid-overload-in-patients-with-heart-failure-novel-approaches-to-remote-monitoring/15311/How can we reduce heart failure hospital readmissions? Experts discuss remote monitoring strategies with the potential to improve patient care.Updates in Glomerular Disease
https://reachmd.com/programs/cme/updates-in-glomerular-disease/14891/Explore cases of IgAN, FSGS, and AAV to further your knowledge of the underlying mechanisms of glomerulonephritis and sclerosis and improve outcomes.Best Practices in Nutrition, Drug Management, and Multi-Organ Support in Patients with AKI
https://reachmd.com/programs/kdigo-conversations-nephrology/best-practices-in-nutrition-drug-management-and-multi-organ-support-in-patients-with-aki/14171/How are the kidneys of critically ill patients affected by their drug regimens? And what are the best practices for managing this?Assessing Approvals: FDA Updates on Dexmedetomidine Hydrochloride
https://reachmd.com/programs/the-drug-report/assessing-approvals-fda-updates-on-dexmedetomidine-hydrochloride/12090/The U.S. Food and Drug Administration approves Aurobindo Pharma’s dexmedetomidine hydrochloride in 0.9% sodium chloride injection.Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis
https://reachmd.com/programs/practical-dermatology/seborrheic-dermatitis-update-a-review-of-the-etiology-and-treatment-of-seborrheic-dermatitis/24003/Seborrheic dermatitis (SD) is an inflammatory skin condition that often involves flaky, erythematous patches on sebum-rich areas of the body such as the face and scalp.1 At least 50 million Americans have a form of seborrheic dermatitis on the scalp, more commonly known as dandruff. SD presents in aCase Review: Targets Are Met—Can You Stick the Landing?
https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Alloimmune Neutropenia of the Fetus and Newborn
https://reachmd.com/programs/cme/alloimmune-neutropenia-of-the-fetus-and-newborn/13910/NAIN is rare and potentially life-threatening. What clues can increase your awareness and help you modify the clinical course of this disease?The Patient-Clinician Connection in Managing CKD-aP
https://reachmd.com/programs/cme/the-patient-clinician-connection-in-managing-ckd-ap/36302/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.